Author Response to Letter to the Editor: Evaluation of Clemastine Effects on Clinical and Electrodiagnostic Parameters in Carpal Tunnel Syndrome (CTS) Patients: A Preliminary Placebo-Controlled Double Blind RCT Authors: Gholamreza Raissi, Tannaz Ahadi, Kamyar Kazemi, Seyed Pezhman Madani, Simin Sajadi, Hosna Soleymanzadeh, Negar Kariznoee Published: 2026 We thank the authors of the referenced “Letter to the Editor”1 for their interest in our preliminary double-blind, placebo-controlled randomized trial evaluating clemastine as an adjunct to night splinting in patients with mild to moderate carpal tunnel syndrome (CTS).2 We appreciate the opportunity to respond to their comments and to clarify several points that may assist readers in interpreting our findings. The authors’ comments highlight a perceived discrepancy in sex distribution between the text and Table 1 regarding baseline characteristics. We wish to explain that Table 1 precisely presents the baseline sex distribution: 5 men and 7 women in the clemastine group and 2 men and 10 women in the placebo group, with a P value of 0.17, indicating no statistically significant difference between the groups. The accompanying text was intended to reflect these data. As such, we are unable to identify a true discrepancy, and we respectfully suggest that specifying the exact source of concern—or reconsidering this statement—would help avoid potential confusion for readers. The commentary also raises concerns regarding statistical significance in light of the Bonferroni adjusted threshold (P < 0.01). We confirm that all between-group comparisons of the primary outcomes, namely the Boston Questionnaire Symptom Severity Scale and Functional Status Scale, met this corrected threshold. P values exceeding this level were not interpreted as statistically significant for between-group effects. If the concern pertains to within-group changes or exploratory secondary analyses, we agree that clearer distinction between adjusted between-group comparisons and descriptive within-group findings may enhance clarity, and we would be pleased to elaborate further if needed. We value the authors’ focus on the integrity of blinding and the reporting of adverse events. The paper indicates that 2 participants in the clemastine group experienced minor sleepiness, which subsided with a modification in the schedule of medication delivery, and no severe adverse effects were noted in either group. Although a formal assessment of blinding success was not performed, the study was conducted using standard double-blind procedures, with allocation concealed from both participants and investigators throughout follow-up. We acknowledge that subsequent research—especially larger, confirmatory trials—would be enhanced by proper blinding evaluations and more comprehensive adverse event documentation. Concerning safety considerations and extrapolation from multiple sclerosis trials, we recognize the necessity of precaution when broadening the application of clemastine to other indications. Nonetheless, we believe that these findings must be understood within context. The cited multiple sclerosis study3 involved a different patient population, disease mechanism, and endpoint hierarchy, and our trial employed a relatively low dose of clemastine (1 mg nightly). Importantly, no serious adverse events were observed in the CTS cohort. Safety profiles may reasonably differ by population, dose, and indication, and we feel this distinction is important when interpreting potential risks. We also value the feedback concerning tone and phrasing. Our study was clearly designated as preliminary, with an open recognition of its limitations, such as a small sample size and the absence of a formal power calculation. We concur that language highlighting opportunities for further clarification, rather than internal inconsistencies, may more accurately represent the exploratory essence of early-phase clinical research and promote constructive scientific dialogue. Finally, the commentary suggests reporting the number of participants achieving a clinically meaningful change on the Boston Questionnaire Symptom Severity Scale. We point out that minimal clinically important difference values were included in the manuscript and that improvements observed in the clemastine group exceeded these thresholds. Explicitly presenting responder proportions may further improve clinical interpretability and is a valuable consideration for future analyses. In summary, we are grateful for the thoughtful engagement with our work. We believe that the explanations provided here address the key points stated and support the analysis of our findings within the context of a preliminary randomized trial. We anticipate that this exchange will enhance the existing discussion and guide the design of future, adequately powered research investigating medications for CTS. Disclosures None. References